Nalu Announces Additional Industry Veterans to Join its Commercial Leadership Team
by CARLSBAD, Calif. (PRWEB) September 28, 2020
Nalu Medical, Inc. (“Nalu”), a global medical device company that provides miniaturized Neuromodulation implants for the treatment of intractable chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), today announced the addition of three senior leaders to the commercial organization, including the appointment of Allen Meacham as Chief Business Development Officer.
In this critical role, Mr. Meacham will be responsible for leading, developing and executing Nalu’s sales strategies to drive growth. Mr. Meacham brings with him over 25 years of senior sales leadership and sales training experience, most recently from Boston Scientific, where he spent the last 15 years building and leading their commercial business for the Spinal Cord Stimulator (SCS) and Deep Brain Stimulator (DBS) divisions.
Earl Fender, Nalu’s President and Chief Executive Officer is confident that, “Allen Meacham’s proven track record makes him uniquely positioned to lead Nalu’s commercial efforts to effectively scale our organization and achieve significant growth in the years ahead.”
Additionally, Alan Mock has joined Nalu as Director of Marketing. Mr. Mock is a seasoned leader with more than 30 years of experience in the medical device industry, the last 23 years in the neuromodulation business with Advanced Neuromodulation Systems, St. Jude Medical Neuromodulation and Nuvectra, in various senior sales and marketing leadership roles.
Nalu also welcomes Ron Kuykendall to lead sales training. Mr. Kuykendall is a neuromodulation veteran with over 20 years of sales training, employee coaching & development, sales management and marketing experience with Advanced Neuromodulation Systems, St. Jude Medical Neuromodulation and Nuvectra.
With these key hires, Nalu’s Chief Commercial Officer, Jon Ruais will continue to build the commercial organization while also developing rapid market growth strategies for SCS and PNS in his new role as Chief Commercial and Strategy Officer; his sales responsibilities will shift to Allen Meacham.
“We are excited to expand and strengthen our commercial leadership team with these outstanding individuals, whose deep knowledge of the neuromodulation business will help continue the momentum and propel us more rapidly toward a broader U.S. launch,” said Mr. Fender. “I would also like to recognize and thank Jon Ruais for his outstanding contribution in commercializing the Nalu system and leading our sales efforts these past 12 months.”
About Nalu Medical
Nalu Medical, Inc. is a privately-held, medical device company located in Carlsbad, California. Our team of seasoned medical device professionals have developed the next generation of miniaturized medical devices. The result is a novel, versatile and upgradeable technology platform that we believe will allow us to address several poorly met needs in the market. Our mission is to modernize, improve, and broaden the therapeutic capabilities of miniaturized medical devices, thus improving lives of people today and addressing the demands of medicine tomorrow.
About the Nalu Neurostimulation System
The Nalu Neurostimulation System, an implanted treatment for managing intractable chronic pain, consists of a fully-featured micro-Implantable Pulse Generator (mIPG™) free of an implantable battery and powered by an externally worn Therapy Disc and controlled by the patient via a smartphone app. The Nalu mIPG is built upon the nPower™ microchip platform that delivers outputs similar to larger IPGs but with additional capabilities around waveforms, programming modes and upgradability. The Nalu mIPG is currently cleared by the FDA for both Spinal Cord Stimulation and Peripheral Nerve Stimulation indications with an expected service life of 18 years. To learn more, visit www.nalumed.com.
Indications for Use
Spinal Cord Stimulation – The Nalu SCS system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Peripheral Nerve Stimulation – The Nalu PNS system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Nalu, the Nalu logo, mIPG and nPower are trademarks of Nalu Medical, Inc.